Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
Stopped FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022 because it was not feasible for the company to complete the required postmarketing clinical trials.
Conditions
- Diffuse Intrinsic Pontine Glioma
- Diffuse Pontine and Thalamic Gliomas
- Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
- DRUG: Panobinostat 15 MG
- DEVICE: Focused Ultrasound with neuro-navigator-controlled sonication
Sponsor
Columbia University
Collaborators